Tardive Dyskinesia Treatment Market Report 2025

The tardive dyskinesia treatment market size has grown strongly in recent years. It will grow from $2.4 billion in 2024 to $2.61 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to the rising use of antipsychotic medications, increasing awareness of drug-induced movement disorders, a higher incidence of schizophrenia and bipolar disorders, greater off-label use of antipsychotics, and the expanding geriatric population using psychotropic drugs.

The tardive dyskinesia treatment market size is expected to see strong growth in the next few years. It will grow to $3.61 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to the increasing demand for safer antipsychotic therapies, rising awareness through advocacy and education initiatives, a stronger focus on personalized mental health treatments, higher healthcare spending on neurological and psychiatric disorders, and the growing number of psychiatric patients requiring long-term therapy. Key trends anticipated during this period include the development of neuroprotective strategies, advancement of dual-action therapies, incorporation of real-world evidence (RWE) in drug evaluation, integration of digital biomarkers, and innovations in non-dopaminergic therapeutic approaches.

The increasing prevalence of psychiatric disorders is expected to drive the growth of the tardive dyskinesia treatment market in the coming years. Psychiatric disorders encompass a wide range of mental health conditions that affect mood, thinking, behavior, and overall functioning, often requiring medical diagnosis and treatment. Their rising prevalence is linked to growing stress and lifestyle pressures caused by heavy workloads, social isolation, and limited time for self-care. Tardive dyskinesia treatments help manage involuntary movement symptoms, thereby improving treatment outcomes and quality of life for patients with psychiatric disorders who require long-term antipsychotic medications. For example, in March 2024, the House of Commons Library, a UK-based research and information service, reported that the proportion of 17- to 19-year-olds with a probable mental disorder rose from 17% in 2021 to 26% in 2022. As a result, the increasing prevalence of psychiatric disorders is fueling demand for tardive dyskinesia treatments.

Companies in the tardive dyskinesia treatment market are focusing on innovative drug formulations, such as sprinkle capsules, to improve adherence among patients with swallowing difficulties. Sprinkle capsule formulations are designed to be opened and mixed with soft food, making them easier to take for patients with dysphagia or difficulty swallowing whole capsules. For instance, in July 2024, Neurocrine Biosciences Inc., a US-based biotechnology company, launched Ingrezza sprinkle (valbenazine) capsules, the leading prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease. This VMAT2 inhibitor helps regulate dopamine levels in the brain to manage involuntary movements and is available as a once-daily oral capsule, including a sprinkle formulation for easier administration in patients with swallowing challenges.

In April 2025, Johnson & Johnson, a US-based pharmaceutical company, acquired Intra-Cellular Therapies for an undisclosed amount. This acquisition allows Johnson & Johnson to strengthen its neuroscience leadership and expand its position in the growing mental health treatment market. Intra-Cellular Therapies Inc. is a US-based pharmaceutical company specializing in treatments for tardive dyskinesia.

Major players in the tardive dyskinesia treatment market are AbbVie Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co Ltd., H. Lundbeck A/S, Zydus Lifesciences Limited, Neurocrine Biosciences Inc., Luye Pharma Group Ltd., Acadia Pharmaceuticals Inc., Upsher-Smith Laboratories LLC, SteriMax Inc., Adamas Pharmaceuticals Inc., ChemWerth Inc, Sunovion Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Synnat Pharma Pvt. Ltd, LGM Pharma LLC, and SOM Biotech S.A.

North America was the largest region in the tardive dyskinesia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tardive dyskinesia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the tardive dyskinesia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Tardive dyskinesia treatment involves medical management and therapeutic approaches designed to reduce or control the involuntary, repetitive movements that result from long-term use of dopamine receptor-blocking agents, particularly antipsychotic medications.

The primary treatment types include medications, botulinum toxin injections, deep brain stimulation, and other therapeutic options. Medications are drugs specifically prescribed to manage and lessen the involuntary movements associated with prolonged antipsychotic use, with commonly used options including valbenazine, amantadine, tetrabenazine, clonazepam, and others. These treatments can be administered through different routes such as oral administration, injections, or transdermal patches. Distribution takes place through hospital pharmacies, retail pharmacies, and other channels, serving various end users including hospitals, specialty clinics, and others.

The tardive dyskinesia treatment market research report is one of a series of new reports that provides tardive dyskinesia treatment market statistics, including tardive dyskinesia treatment industry global market size, regional shares, competitors with a tardive dyskinesia treatment market share, detailed tardive dyskinesia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the tardive dyskinesia treatment industry. This tardive dyskinesia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tardive dyskinesia treatment market includes revenues earned by entities through botulinum toxin injection services, deep brain stimulation procedures, and diagnostic and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.